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Abstract
Lupus nephritis is a potentially reversible cause of severe acute kidney injury
and is an important cause of end-stage renal failure in Asians and patients of
African or Hispanic descent. It is characterized by aberrant exaggerated innate
and adaptive immune responses, autoantibody production and their deposition
in the kidney parenchyma, triggering complement activation, activation and
proliferation of resident renal cells, and expression of pro-inflammatory and
chemotactic molecules leading to the influx of inflammatory cells, all of which
culminate in destruction of normal nephrons and their replacement by fibrous
tissue. Anti-double-stranded DNA (anti-dsDNA) antibody level correlates with
disease activity in most patients. There is evidence that apart from mediating
pathogenic processes through the formation of immune complexes, pathogenic
anti-dsDNA antibodies can bind to resident renal cells and induce downstream
pro-apoptotic, pro-inflammatory, or pro-fibrotic processes or a combination of
these. Recent data also highlight the critical role of macrophages in acute and
chronic kidney injury. Though clinically effective, current treatments for lupus
nephritis encompass non-specific immunosuppression and the
anti-inflammatory action of high-dose corticosteroids. The clinical and
histological impact of novel biologics targeting pro-inflammatory molecules
remains to be investigated. Insight into the underlying mechanisms that induce
inflammatory and fibrotic processes in the kidney of lupus nephritis could
present opportunities for more specific novel treatment options to improve
clinical outcomes while minimizing off-target untoward effects. This review
discusses recent advances in the understanding of pathogenic mechanisms
leading to inflammation and fibrosis of the kidney in lupus nephritis in the
context of established standard-of-care and emerging therapies.
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Introduction
Lupus nephritis (LN) is a severe manifestation of systemic lupus 
erythematosus (SLE) and is associated with a sixfold increase in 
mortality compared with the general population1. Up to 60% of 
patients with SLE will develop LN at some stage during the course 
of disease, the percentage depending on race, ethnicity, and health-
care availability1–3. LN is characterized by loss of self-tolerance, 
production of autoantibodies to nuclear autoantigens, immune 
complex deposition, and immune-mediated injury to the kidney 
parenchyma. Clinically, LN is characterized by periods of remis-
sion interspersed with episodes of disease activity or flares. If these 
inflammatory processes are not effectively and rapidly control-
led, glomerulosclerosis, interstitial fibrosis, tubular atrophy, and 
progressive kidney failure will follow, leading to end-stage renal 
failure requiring renal replacement therapy. Treatment of LN has 
evolved considerably over the past few decades from reliance on 
corticosteroids alone to different combination immunosuppres-
sive regimens, and the optimal choice is informed by the type 
and severity of nephritis, the phase in the natural history of dis-
ease, and patient characteristics4. It has been reported that approxi-
mately 30% of patients eventually will progress to end-stage renal 
failure3,5. Identifying key elements in the pathogenesis of inflam-
mation and fibrosis or important checkpoints leading to kidney 
damage could present opportunities for novel means of therapeutic 
intervention to further improve clinical outcomes.
Overview of lupus nephritis pathogenesis
LN is initiated by the deposition of anti-double-stranded DNA 
(anti-dsDNA) antibody-containing immune complexes in the 
kidney parenchyma resulting in complement activation, infiltra-
tion of immune cells, increased activation and proliferation of 
resident renal cells, and immune-mediated kidney injury. The pre-
cise location of immune complexes in the glomerulus and tubulo- 
interstitium, their size, ability to activate complement, and the 
effectiveness of complex-clearing mechanisms dictate the sever-
ity of proliferative and inflammatory responses in the kidney. 
The glomerulus is the predominant site for immune complex 
deposition. Deposition within the mesangium is accompanied by 
mesangial hypercellularity and increased matrix synthesis, whereas 
their deposition in the subendothelium induces endothelial cell 
injury, endocapillary proliferation and infiltration of circulating 
myeloid cells into the kidney6. Injury to endothelial cells induces 
the release of apoptotic microparticles that drive dendritic cell 
activation and prime neutrophils for NETosis, which further 
exacerbates inflammatory processes7. Subepithelial deposits pro-
mote podocyte injury with restricted immune cell infiltration 
unless the glomerular basement membrane (GBM) ruptures8. The 
most severe forms of LN (classes III and IV) are characterized by 
inflammatory and proliferative glomerular lesions resulting in 
fibrosis and loss of renal function9. Immune deposits have also 
been detected in the tubular basement membrane in up to 70% of 
patients with LN, especially those with class III or IV LN, and 
the quantity of immune complex deposition correlates with the 
severity of tubulo-interstitial inflammation10,11.
Anti-dsDNA antibody production is a cardinal feature of LN, 
and serum levels often correlate with disease activity12,13. There 
is evidence that in addition to contributing to immune complex 
formation, pathogenic anti-dsDNA antibodies can bind to resi-
dent renal cells and induce downstream apoptotic, inflammatory, 
and fibrotic processes10,12,14–20. There is increasing evidence to sug-
gest that the pathogenic potential of anti-dsDNA antibodies is not 
dependent on its interaction with dsDNA per se since dsDNA is 
poorly immunogenic21 but is instead reliant on its poly-reactive 
nature and ability to bind to cross-reactive antigens on the sur-
face of resident renal cells or constituents of their extracellular 
matrix22–24. Many of the studies relating to anti-dsDNA antibodies 
binding to resident renal cells have focused on mesangial cells and 
currently there are limited data on the interaction of anti-dsDNA 
antibodies with glomerular endothelial cells, podocytes, and 
proximal tubular epithelial cells (PTECs). Anti-dsDNA antibodies 
have also been reported to bind to nucleosomes that are released 
into the circulation from either circulating or intra-glomerular apop-
totic cells, which are then entrapped within the GBM. Recently, 
Olin et al. demonstrated that laminin β1, an extracellular matrix 
component induced in resident renal cells by transforming growth 
factor-beta 1 (TGF-β1) during tissue fibrosis, entrapped nucleo-
somes in electron-dense deposits in the GBM which could serve 
as antigens for anti-dsDNA antibodies25. Although there has been 
much debate on the mechanisms that mediate anti-dsDNA anti-
body binding to the kidney parenchyma, distinct mechanisms may 
operate in different renal compartments and possibly at different 
phases of disease.
The pathogenic mechanisms of anti-dsDNA antibodies remain 
controversial. Non-dsDNA-binding antibodies may also contrib-
ute to kidney injury. Dissociation between anti-dsDNA antibody 
deposition and LN has also been reported in experimental models 
of LN. In NZM2328.Lc4 mice, intra-glomerular immune complex 
deposition and fatal LN occurred in the absence of anti-dsDNA 
antibodies26. Furthermore, lupus-prone mice deficient in Stat4, a 
transcription factor that drives Th1 responses, displayed acceler-
ated nephritis compared with their wild-type littermates in the 
absence of anti-dsDNA antibodies27. The mode of kidney inflam-
mation could be more important than anti-dsDNA antibodies 
per se in the initiation and progression of LN27. Biopsy-proven 
LN can occur in patients without anti-dsDNA antibodies in the 
circulation28. Discordance between circulating anti-dsDNA 
antibody titres and activity of LN may also be attributed to the 
different dsDNA substrates used in immunoassays29.
Recent knowledge on renal inflammation in lupus 
nephritis
(a) Role of resident kidney cells
The mesangium is the site for anti-dsDNA antibody-containing 
immune complex deposition in the glomerulus in less severe 
forms of LN, and mesangial immune deposits are always present 
in severe nephritis. We22 and others23,30 have reported that anti-
dsDNA antibodies can bind directly to mesangial cells through 
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cell surface annexin II or α-actinin. The functional consequence of 
anti-dsDNA antibody binding to α-actinin on mesangial cells has 
not been defined. Binding of anti-dsDNA antibodies to mesangial 
annexin II resulted in the activation of mitogen-activated protein 
kinase (MAPK) and AKT/phosphoinositide 3-kinase (AKT/PI3K) 
signaling pathways and increased IL-6 secretion and annexin II 
expression. That anti-dsDNA antibodies can augment increased 
annexin II expression in mesangial cells suggests potential ampli-
fication of immune-mediated inflammation in the glomerulus22. 
At the ultrastructural level, annexin II localized to the surface 
of mesangial cells and in the mesangial matrix and also with 
electron-dense immune deposits along the GBM31. Annexin II 
can co-localize with immunoglobulin G (IgG) and complement 3 
(C3) deposition in human and murine LN, thus underscoring the 
pathogenic role of annexin II and its interaction with anti-dsDNA 
antibodies in LN22. Anti-dsDNA antibodies can induce gene 
or protein expression (or both) of pro-inflammatory mediators 
such as interleukin-1 beta (IL-1β), tumor necrosis factor- 
alpha (TNF-α), hyaluronan, lipocalin-2, monocyte chemoat-
tractant protein-1 (MCP-1), (C-X-C motif) ligand 1 (CXCL1)/
KC, CX3CL, and inducible nitric oxide synthase in cultured 
human or murine mesangial cells15,17,22,32. The induction of these 
pro-inflammatory mediators is facilitated through the binding of 
high-mobility group box 1 protein, engagement of Toll-like recep-
tor 2 (TLR-2) and receptor for advanced glycation end-products 
(RAGE), activation of the MAPK, protein kinase C (PKC), inhibi-
tor of kappa-light chain-enhancer of activated B cells (IκB) and 
nuclear factor kappa B (NF-κB) signaling pathways, and endo-
plasmic reticulum stress20,32–35. Correlation between serum levels 
of IL-1β, IL-6, TNF-α, hyaluronan, and lipocalin and disease 
activity in patients with SLE further highlights the importance of 
these inflammatory markers in the pathogenesis of LN17,36–39.
The severity of tubulo-interstitial inflammation and injury 
strongly correlates with poor renal prognosis40. We reported that 
anti-dsDNA antibodies isolated from patients with LN during 
nephritic flare can induce secretion of pro-inflammatory mediators 
such as IL-6, IL-8, TNF-α, and MCP-1 through distinct MAPK 
pathways in cultured PTECs14,39 and contribute to the establishment 
of chemotactic gradients that permit infiltration of immune cells 
into the tubulo-interstitium. Bi-directional communication occurs 
between mesangial cells and PTECs, and inflammatory responses 
occurring in either kidney compartment induced by anti-dsDNA 
antibodies can provoke a response in the other compartment10. 
Anti-dsDNA antibodies isolated from LN patients in remission can 
also induce IL-6 secretion in PTECs10, a pro-inflammatory cytokine 
that promotes B-cell differentiation and autoantibody production. 
Increased IL-6 expression is observed in the kidneys of patients and 
mice with LN, and infiltrating monocytes/macrophages, mesangial 
cells, and PTECs are thought to be the predominant source. The 
findings suggest the possibility of subclinical inflammation, which 
has important implications on the choice and dose of maintenance 
immunosuppressive therapy. Current methods for monitoring 
disease activity do not reliably assess kidney inflammation and 
fibrosis, and the search for biomarkers which could serve such 
purposes is ongoing41,42.
Of the multitude of pro-inflammatory mediators synthesized by 
immune and resident renal cells in LN, interferon (IFN) has been 
implicated in both systemic and end-organ inflammation43. Patients 
with lupus exhibit increased expression of type I IFN response 
genes43. The importance of type I IFN in the development of LN 
stems from experimental and clinical studies that show reduced 
autoimmunity in type I IFN receptor-deficient lupus-prone mice44, 
exacerbation of disease following administration of adenovirus 
encoding IFN-α to lupus-prone mice9,45, and the production of 
lupus-related antibodies in a significant percentage of patients 
whose hepatitis C was treated with IFN-α46. Whether plasma-
cytoid dendritic cells are the main source of type I IFN remains 
controversial. In a murine model of anti-GBM nephritis, resident 
renal cells rather than infiltrating leukocytes were shown to be the 
dominant source of type I IFN in the kidney which augmented 
immune-mediated injury47, possibly through TLR-3 activation48. 
Although the investigators did not identify which cells synthe-
sized type I IFN, it is possible that mesangial cells contribute49. 
Regulation of type I IFN in mesangial cells is mediated at least 
in part by microRNA (miR)-130b, and miR-130b expression is 
decreased in renal specimens from patients and mice with LN50.
(b) Role of infiltrating cells
Both innate and adaptive immune systems play critical roles in 
systemic and intra-renal inflammatory response in LN. Intra-
renal deposition of IgG-containing immune complexes alone is 
insufficient to initiate pathogenesis and must be accompanied 
by secretion of pro-inflammatory mediators and recruitment of 
immune cells. Multiple effector mechanisms have been identi-
fied in lupus-prone mice and these include but are not limited to 
Fc receptors (FcRs), type I IFN receptors, IL-6, and MCP-151–54. 
Engagement of IgG-containing immune complexes with FcRs is a 
critical step in the development of LN. Although FcRs are present 
on mesangial cells, FcR activation on circulating hematopoi-
etic cells rather than resident renal cells initiates pathogenesis in 
lupus-prone mice51. Also, the accumulation of apoptotic debris 
in hematopoietic cells has been reported to promote FcγRI- 
mediated PI3K signal transduction and disease development 
in lupus-prone mice, whereas mice deficient in FcγRI were 
protected55. Monocytes isolated from patients with LN express 
increased FcγRI and exhibit increased MCP-1 secretion and 
chemotactic potential compared with monocytes from healthy 
subjects56.
Increased serum type I IFN level and induction of IFN-induced 
gene transcript and protein signature have been observed in 
peripheral blood mononuclear cells (PBMCs) and renal tissue in 
patients with LN43. Serum IFN-α in pediatric patients with lupus 
can induce monocyte maturation into highly active antigen-
presenting dendritic cells57. These myeloid cells activate naïve 
T cells and stimulate B-cell expansion and differentiation through 
B cell-activating factor (BAFF) and exacerbate autoantibody 
production and autoimmunity. Exogenous viruses have been sug-
gested as a possible trigger of SLE since double-stranded RNA 
(dsRNA) viruses can induce IFN-α secretion in dendritic cells, 
but with the possible exception of Epstein-Barr virus, there are 
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limited data to implicate viruses in SLE. Rather, self nucleic acid- 
containing immune complexes can activate TLRs, which mediate 
downstream induction of type I IFN synthesis in PBMCs. Expres-
sion of long interspersed nuclear element 1, a virus-derived nucleic 
acid present as a transposable element in the human genome, has 
recently been reported to induce type I IFN in PBMCs and may 
contribute to the initiation and amplification of SLE58. Oxidative 
stress, mitochondrial dysfunction, and opsonization of apop-
totic cells by complement and IgM have also been implicated in 
increased type I IFN production and NF-κB activation in periph-
eral blood lymphocytes in patients with SLE59,60. Assessment of 
IFN-inducible gene expression signature rather than IFN secre-
tion may be a more sensitive method to determine IFN activation 
in patients with lupus and this is due to blocking antibodies that 
may be present in serum43. The roles of IL-6 and MCP-1 in the 
pathogenesis of LN are well established and have been reviewed 
elsewhere61,62.
Chemokine production by infiltrating and resident renal cells 
mediates the recruitment of monocytes from the circulation 
and their differentiation into macrophages as they migrate to 
the site of injury. Macrophages can be divided into two subsets, 
namely M1 and M2 macrophages63. M1 macrophages are classic 
phagocytic, inflammatory macrophages and are activated in 
response to IFN-γ or TNF-α to secrete large quantities of pro-
inflammatory cytokines that include IL-1, IL-6, IL-12, and IL-
23. M1 macrophages recruit neutrophils to the site of injury and 
also induce Th1 and Th17 differentiation64. M2 macrophages 
are activated by IL-4 and can be subdivided into three groups 
comprising M2a macrophages that contribute to the reparative 
process and secretion of anti-inflammatory cytokines, M2b mac-
rophages that are induced by immune complexes or TLR ligation, 
and M2c macrophages that possess anti-inflammatory and pro- 
fibrotic properties and play a key role in the elimination of apop-
totic cells63,65. Owing to their plasticity and presence of pro- or 
anti-inflammatory cytokine levels within their microenviron-
ment, macrophages can switch from an M1 to an M2 phenotype65. 
Macrophages are key cellular determinants in the pathogen-
esis of LN and are an important source of key pro-inflammatory 
cytokines that drive autoimmunity66. Their detection in renal 
biopsies from patients with LN is associated with crescent for-
mation and poor renal prognosis67,68. It has been reported that 
M1 macrophages were more abundant in class IV LN com-
pared with class II and V LN and were detected predominately 
in the glomerulus68. Macrophages present in tubulo-interstitium 
belonged to the M2c subgroup, and their number correlated 
with tubulo-interstitial injury score, anti-dsDNA antibody level, 
and severity of renal impairment, suggesting a putative role of 
these cells in tubulo-interstitial injury or fibrosis68. The clinical 
relevance of M2c macrophages is also substantiated by elevated 
plasma levels of sCD163 (released from M2c macrophages) during 
active SLE69. Depletion of macrophages using a specific inhibitor 
to the colony-stimulating factor-1 (CSF-1) receptor in an inducible 
murine model of LN protected mice from renal inflammation 
and development of nephritis70. Lupus-prone mice deficient in 
MCP-1 exhibited reduced numbers of interstitial macrophages, 
decreased proteinuria, and improvement in renal histology54. 
The role of macrophages in experimental models of LN is 
dependent on the mouse model used and disease status. In the 
human setting, CD169+ inflammatory macrophages are present 
in the glomeruli of patients with LN, but not healthy subjects, 
and their number correlated with the severity of proteinuria. 
Glomerular CD169+ macrophages decreased in number after 
corticosteroid treatment71.
B cells are central to LN pathogenesis since they are precursors 
for autoantibody-producing plasma cells, present antigens to 
T cells, and contribute to cytokine secretion. Vimentin expressed 
by infiltrating inflammatory cells has been reported to serve 
as an autoantigen that induced in situ B-cell selection during 
tubulo-interstitial inflammation in LN72. Activated macrophages 
secrete vimentin in response to pro-inflammatory signaling73 
and may be a source of vimentin in the tubulo-interstitium. 
Alternatively, PTECs undergoing epithelial-to-mesenchymal tran-
sition (EMT) and apoptosis may also contribute to the vimentin 
repertoire in the kidney since vimentin is an intermediate filament 
synthesized by mesenchymal cells and is also expressed on the 
cell surface of apoptotic cells74,75. Post-translational modification 
of vimentin may increase its antigenicity and exacerbate autoim-
munity76. Elevated anti-vimentin antibody levels are observed in 
patients with LN, and the level of these antibodies correlated with 
tubulo-interstitial inflammation72. Yet how these autoantibodies 
contribute to tubulo-interstitial injury remains to be investigated. 
Anti-vimentin antibodies have also been detected in a proportion 
of recipients with renal or cardiac allograft, and mycopheno-
late (MPA) treatment was associated with lower anti-vimentin 
antibody levels compared with azathioprine in cardiac allograft 
recipients77,78.
Recent knowledge on renal fibrosis in lupus 
nephritis
Renal fibrosis is a common feature of chronic inflammatory 
disorders where wound-healing processes persist and become 
excessive, with prolonged production of growth factors, fibrogenic 
cytokines and proteolytic enzymes and their inhibitors, leading to 
increased synthesis and decreased degradation of the extracellular 
matrix. Both resident renal cells and immune cells contribute to 
kidney fibrosis.
(a) Role of resident kidney cells
Appropriate regulation of inflammation is essential to prevent 
progressive kidney fibrosis in LN. Fibronectin is the predomi-
nant matrix protein present in glomerulosclerotic lesions and is 
one of the first matrix components to be deposited during tubulo- 
interstitial fibrosis79,80. Intra-glomerular fibronectin expression is 
increased in patients and mice with active LN15,16 and co-localizes 
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with IgG deposition, suggesting an association between autoanti-
body deposition and matrix protein accumulation16. We reported 
that anti-dsDNA antibodies can induce both soluble and fibril-
lar fibronectin synthesis in mesangial cells and PTECs through 
increased PKC and MAPK signaling and TGF-β1, MCP-1, 
IL-6, IL-8, and TNF-α secretion14,16. Our observation that pro- 
inflammatory mediators can also contribute to increased fibrogen-
esis highlights their multi-faceted functions during pathogenesis. 
The role of TGF-β1 as a key mediator of kidney fibrosis is well 
established81,82, but it is noteworthy that TGF-β1 also plays an 
important role in immune regulation and can suppress B-cell 
auto-reactivity during the early phase of disease but can exert 
pro-fibrotic actions when LN is established81,83. Fibrogenic cells 
are characterized by their ability to synthesize fibrillar collagen. 
We demonstrated that soluble fibronectin can induce TGF-β1 and 
collagen synthesis in PTECs, thereby amplifying the fibrogenic 
response of anti-dsDNA antibodies in the tubulo-interstitium14. 
Increased fibronectin has been reported to induce EMT in lung 
alveolar epithelial cells84. It is possible that anti-dsDNA anti-
body induction of fibronectin induces EMT in PTECs, although 
further studies are warranted to confirm this. In this regard, we 
have demonstrated that anti-dsDNA antibodies derived from 
patients with LN during active disease and remission can induce 
phenotypic changes in PTECs with the acquisition of an elon-
gated, fibroblastic appearance10. Myofibroblasts are the primary 
source of matrix proteins in renal fibrosis, and these cells may 
originate from PTECs undergoing EMT, interstitial fibroblasts, 
or pericytes85,86. There is emerging evidence that epigenetics may 
contribute to the progression of renal fibrosis, and miR-150 has 
been implicated in tubulo-interstitial fibrosis in patients with LN 
through its ability to repress suppressor of cytokine signaling 187. 
In a murine model of chronic kidney disease, reduced fatty acid 
oxidation in renal tubular epithelial cells appeared to contribute 
to kidney fibrosis, possibly through mitochondrial dysfunction88. 
The role of fatty acid oxidation in tubular epithelial cells and 
tubulo-interstitial fibrosis in LN is not known.
(b) Role of infiltrating cells
Monocyte-derived macrophages play an important role in tissue 
fibrosis through direct effects on matrix remodeling or indirectly 
through the activation of myofibroblasts. Unlike pro-inflammatory 
M1 macrophages, M2 macrophages exert anti-inflammatory 
responses and contribute to reparative processes following tis-
sue injury. In immune-mediated injury where the inciting factors 
persist, M2 macrophages drives fibrogenesis through increased 
synthesis of growth factors, polyamine and proline89 and the 
generation of a provisional matrix that promotes recruitment 
and activation of fibroblasts. In animal studies, depletion of 
macrophages has been shown to reduce the severity of crescen-
tic glomerulonephritis and tubulo-interstitial fibrosis90–92. Bone 
marrow-derived M2 macrophages can undergo myofibroblastic 
transition and contribute to collagen and α-smooth muscle actin 
expression in areas of kidney fibrosis in patients with IgA neph-
ropathy or rapidly progressive glomerulonephritis93. It is possible 
that M2 macrophages also contribute to kidney fibrosis through a 
similar mechanism in LN. Although α-smooth muscle actin is 
often associated with myofibroblasts, there is evidence that it 
is also expressed in the kidney of healthy subjects and neonatal 
pericytes and thus is not a reliable marker for myofibroblasts94. 
Instead, fibrillar collagen has been suggested to be a more appro-
priate marker94. Of note, renal myofibroblasts lacking α-smooth 
muscle actin expression are associated with increased cell 
proliferation and collagen production and have been reported to 
contribute to renal fibrosis95.
Current and emerging treatments for lupus nephritis 
and their effects on inflammatory and fibrotic 
processes
Preservation of nephrons is critical in ensuring long-term renal 
and patient survival1. The current standard-of-care induction 
treatments for severe LN are corticosteroids combined with either 
cyclophosphamide (CYC) or MPA96–99. We have reported that 
MPA can exert a beneficial role on inflammatory and fibrotic 
processes induced by anti-dsDNA antibodies in human mesangial 
cells and PTECs and that this role is independent of its immuno-
suppressive actions14–16,39. We have also demonstrated that MPA 
together with methylprednisolone (MP) was more effective than 
CYC and MP in preserving renal histology with reduced severity 
of renal fibrosis in New Zealand black and white first-generation 
(NZB/W F1) mice, possibly through the ability of MPA to 
decrease PKC-α activation and TGF-β1 expression15. Long-term 
follow-up studies have reported a relatively high incidence of 
chronic kidney failure in patients with LN previously treated with 
CYC, especially in subjects with a greater propensity for renal 
fibrosis, such as African-Americans100–102. In a murine model 
of progressive renal interstitial fibrosis, CYC treatment alone 
was shown to induce interstitial fibrosis, which was associated 
with the depletion of macrophages, although the subtype was not 
determined103. Whether exposure to CYC in susceptible indi-
viduals tips the balance in favor of fibrosis instead of repair is an 
intriguing possibility with significant clinical implications. In 
patients with neoplastic diseases, CYC treatment was associated 
with urinary bladder inflammation and fibrosis, and the sever-
ity of fibrosis was associated with the dose and duration of CYC 
treatment104. It was unclear whether the bladder fibrosis was con-
sequent solely to CYC-induced uroepithelial inflammation or 
was aggravated by a separate pro-fibrotic effect of CYC. In addi-
tion to MMF and CYC, azathioprine and calcineurin inhibitors 
are used in the treatment of lupus. Whether these pharmacologic 
agents, in addition to their immunosuppressive actions, can exert 
a direct effect on kidney inflammation has not been investigated. 
In contrast, the chronic nephrotoxicity of calcineurin inhibitors 
has been investigated in organ transplant recipients and is charac-
terized by renal parenchymal fibrosis, vascular hyalinization and 
prominent induction of TGF-β105. Angiotensin-converting enzyme 
(ACE) inhibitors and angiotensin II receptor blockers have been 
shown to reduce proteinuria and the rate of renal function deteri-
oration in patients with chronic glomerular diseases such as dia-
betic nephropathy or IgA nephropathy. In patients with quiescent 
LN and persistent proteinuria, treatment with ACE inhibitors or 
angiotensin II receptor blockers resulted in sustained improve-
ments in proteinuria and serum albumin level106. Treatment of 
lupus-prone mice with ACE inhibitors delayed the onset of pro-
teinuria, reduced disease progression and chronic kidney lesions, 
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and was associated with decreased intra-glomerular expression of 
TGF-β1 and TGF-β2 and splenic production of type 2 cytokines 
such as IL-4 and IL-10107. It is conceivable that treatment of lupus 
patients who have chronic renal damage with blockade of the 
renin-angiotensin pathway should exert a similar beneficial effect 
on kidney fibrosis.
Although high-dose corticosteroids remain a cornerstone in 
the treatment of severe active LN, the use of pulse corticoster-
oids is highly variable between clinicians96–99. Intravenous pulse 
corticosteroid treatment has been reported to be more effective 
than oral corticosteroids in suppressing circulating and intra- 
renal expression of pro-inflammatory cytokines in autoimmune 
conditions, including LN108–110. Although this should theoretically 
be accompanied by reduction of renal inflammation, the impact 
of pulse corticosteroids on renal inflammation and fibrosis 
remains to be examined.
Biological therapies target key molecules in pathogenic 
pathways, based on knowledge of the immunopathogenic mecha-
nisms in LN. Biologics tested or being developed in SLE or LN 
(or both) inhibit B-cell proliferation and activation (for exam-
ple, anti-BAFF), target B-cell subpopulations (for example, anti-
CD20), reduce co-stimulatory signal in T lymphocyte activation 
(for example, cytotoxic T-lymphocyte associated protein 4 (CTLA-
4) Ig), or antagonize the effect of key cytokines (for example, 
IFN-α)111–115. Treatment of lupus-prone mice with anti-BAFF or 
CTLA-4 Ig was shown to ameliorate glomerular inflammation and 
tubular damage and decrease intra-renal inflammatory cytokine 
expression116,117. Anti-IL-6 monoclonal antibodies were shown to 
ameliorate nephritis in murine LN models118,119; yet in a control-
led trial, the anti-IL-6 antibody sirukumab given for 24 weeks 
did not reduce proteinuria that persisted despite standard induc-
tion immunosuppressive treatment for LN, and the treatment was 
associated with excessive serious infections120. TWEAK (TNF-
like weak inducer of apoptosis) is a member of the TNF family 
of cytokines, and the Fn14 gene codes for the TWEAK recep-
tor. Monocytes, dendritic cells, and natural killer cells are the 
major sources of TWEAK. Although transient activation of the 
TWEAK/Fn14 pathway is involved in tissue repair after injury, 
excessive or persistent activation of the pathway is implicated in 
autoimmune diseases, including lupus, and activation of the path-
way in diseased organs has been reported to drive local inflam-
mation leading to fibrosis121. Anti-TWEAK antibody therapy 
has yielded promising results in animal models of autoimmune 
diseases122,123. A phase II randomized placebo-controlled clini-
cal trial that explored the efficacy, tolerability, and safety 
of anti-TWEAK antibody as an add-on therapy in patients with 
class III/IV LN did not demonstrate sufficient efficacy, and 
the drug development program was terminated (ATLAS study, 
NCT01499355).
Apart from positive trial outcomes with belimumab and ani-
frolumab in lupus patients without severe nephritis111,112,124, the 
other clinical trials on biologics to date either failed to achieve the 
efficacy study endpoints or have been aborted because of perceived 
unfavorable balance in effect size versus adverse events114,115,125. 
The data nevertheless suggest that a subset of patients could 
derive clinically observable benefit when these agents were 
added to conventional immunosuppressive therapies for active 
LN113–115. Factors contributing to the apparent discrepancy between 
biological effect and clinical outcomes include efficacy of back-
ground therapy, definition of clinical study outcomes126, and 
patient heterogeneity, the last of which was evidenced by the greater 
impact of rituximab treatment in African-Americans compared 
with Caucasians114. The impact of these agents on renal parenchy-
mal inflammation or fibrosis remains unknown as this is rarely 
an outcome parameter and the data have not been systematically 
examined.
Conclusions
Inflammation and fibrosis are key processes in LN and involve 
the interplay of immune cells of the innate and adaptive immune 
system and resident renal cells. The identification of molecules 
or pathways that contribute to the development of LN has flour-
ished over the past decade and is ever-expanding. Identifying the 
roles of inflammatory mediators and the molecular mechanism 
that regulate inflammatory responses is made more challenging by 
their multi-faceted roles, not only at the onset of pathogenesis but 
also during the effector phase where they facilitate kidney injury. 
Defining how these molecules contribute to disease pathogen-
esis is crucial before more focused therapeutic strategies can be 
devised. Despite a sound mechanistic rationale and encourag-
ing animal data, the clinical results with biologics have been dis-
appointing to date, yet the failure to demonstrate clinical utility 
could reflect deficiencies in protocol design rather than a lack of 
biological effect. There are a number of murine models of LN, 
and choosing an optimal model is imperative to identify key 
checkpoints of kidney injury and in the evaluation of potential 
therapeutic interventions. Table 1 summarizes the phenotypic 
differences between different murine models of LN. Current 
therapies primarily target immunological and inflammatory path-
ways, yet disease mechanisms that lead to myofibroblast con-
version and fibrotic processes should not be overlooked. Lastly, 
given that a multitude of effector mechanisms are activated in 
patients with LN, biological profiling of patients with a proteomics 
or genomics approach (or both) may facilitate better selection of 
treatment regimens.
Abbreviations
ACE, angiotensin-converting enzyme; BAFF, B cell-activating 
factor; CTLA-4, cytotoxic T-lymphocyte associated protein 4; 
CYC, cyclophosphamide; dsDNA, double-stranded DNA; EMT, 
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mycophenolate; NF-κB, nuclear factor kappa B; PBMC, periph-
eral blood mononuclear cell; PI3K, phosphoinositide 3-kinase; 
PKC, protein kinase C; PTEC, proximal tubular epithelial cell; 
SLE, systemic lupus erythematosus; TGF-β1, transforming growth 
factor-beta 1; TLR, Toll-like receptor; TNF-α, tumor necrosis 
factor-alpha; TWEAK, TNF-like weak inducer of apoptosis.
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